Outcomes of Switching From Aflibercept to Faricimab Therapy in Patients With Refractory Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Graefe's Archive for Clinical and Experimental Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration
Graefes Arch. Clin. Exp. Ophthalmol 2024 Jan 01;262(1)43-51, K Kataoka, K Itagaki, N Hashiya, S Wakugawa, K Tanaka, M Nakayama, A Yamamoto, R Mukai, J Honjyo, I Maruko, M Kawai, Y Miyara, N Terao, Y Wakatsuki, H Onoe, R Mori, H Koizumi, T Sekiryu, T Iida, AA OkadaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.